Payment overview · 2025
General Payments
$2,543.56
124 reported records · 26 companies
Healthcare provider profile · identity verified
David R Shober, DO
Allopathic & Osteopathic Physicians|Family Medicine · NEW CASTLE, PA · NPI 1255319042
Verified facts
What the public records show
CMS Open Payments records show David R Shober, DO received $2,543.56 in general payments during 2025 across 124 reported records.
Novo Nordisk Inc accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Edarbi, Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta, Unithroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Synthroid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UNITHROID as an associated drug or biological on 7282 records involving 3230 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Unithroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 342 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGLYZA as an associated drug or biological on 111 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Onglyza by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Edarbi by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 557 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 359 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 557 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $474.39 | 18.6% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $346.29 | 13.6% | 17 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $241.27 | 9.5% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $224.95 | 8.8% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $212.74 | 8.4% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $156.79 | 6.2% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.03 | 5.7% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $126.88 | 5.0% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.67 | 3.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $63.72 | 2.5% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $63.03 | 2.5% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $49.25 | 1.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $46.53 | 1.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.44 | 1.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.26 | 1.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$37.64 | 1.5% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.10 | 1.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.39 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.43 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.20 | 0.8% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $18.00 | 0.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.79 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.38 | 0.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.62 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.40 | 0.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.37 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,533.56 | 123 |
| Education | $10.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $373.09 | 17 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $331.79 | 16 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $212.74 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $207.13 | 15 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $167.97 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $167.97 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $166.21 | 17 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $133.30 | 8 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $126.88 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $101.30 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $98.62 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.37 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $91.69 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $88.74 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $88.74 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $88.74 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.16 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $79.10 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.80 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.66 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $63.72 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $63.72 | 4 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $49.25 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $46.53 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $46.53 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $45.44 | 2 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $40.96 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $29.07 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $3.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 359 | exact normalized | Medicare Part D |
| EDARBI edarbi |
2025 | Edarbi | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 557 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 342 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 301 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 122 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 35 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 201 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 157 | exact normalized | Medicare Part D |
| UNITHROID unithroid |
2025 | Unithroid | 2024 | 50 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
201 | 42 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | UNITHROID open payments reported associated product |
CMS Open Payments — General Payments 7282 supporting records · 3230 recipient NPIs · example record 1220525525 |
Unithroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
342 | 73 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ONGLYZA open payments reported associated product |
CMS Open Payments — General Payments 111 supporting records · 89 recipient NPIs · example record 1206133840 |
Onglyza · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
301 | 64 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
557 | 85 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
252 | 189 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
157 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
301 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
122 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
201 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
359 | 353 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
557 | 85 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
35 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1557 | 378 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1512 | 330 |
| Amlodipine Besylate | Amlodipine Besylate | 1234 | 340 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 992 | 291 |
| Lisinopril | Lisinopril | 899 | 262 |
| Hydrochlorothiazide | Hydrochlorothiazide | 838 | 245 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 737 | 193 |
| Tamsulosin Hcl | Tamsulosin Hcl | 655 | 140 |
| Pravastatin Sodium | Pravastatin Sodium | 625 | 152 |
| Potassium Chloride | Potassium Chloride | 575 | 130 |
| Eliquis | Apixaban | 557 | 85 |
| Metformin Hcl | Metformin Hcl | 529 | 139 |
| Allopurinol | Allopurinol | 508 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 505 | 120 |
| Furosemide | Furosemide | 490 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 449 | 120 |
| Metformin Hcl Er | Metformin Hcl | 440 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 418 | 116 |
| Carvedilol | Carvedilol | 417 | 94 |
| Sertraline Hcl | Sertraline Hcl | 412 | 107 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 359 | 353 |
| Farxiga | Dapagliflozin Propanediol | 342 | 73 |
| Valsartan | Valsartan | 325 | 84 |
| Omeprazole | Omeprazole | 320 | 82 |
| Gabapentin | Gabapentin | 318 | 70 |
| Meloxicam | Meloxicam | 312 | 88 |
| Jardiance | Empagliflozin | 301 | 64 |
| Famotidine | Famotidine | 289 | 79 |
| Citalopram Hbr | Citalopram Hydrobromide | 285 | 54 |
| Ezetimibe | Ezetimibe | 274 | 71 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 252 | 189 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 244 | 111 |
| Montelukast Sodium | Montelukast Sodium | 243 | 52 |
| Vascepa | Icosapent Ethyl | 233 | 40 |
| Finasteride | Finasteride | 210 | 41 |
| Alendronate Sodium | Alendronate Sodium | 204 | 61 |
| Rybelsus | Semaglutide | 201 | 38 |
| Synthroid | Levothyroxine Sodium | 201 | 42 |
| Januvia | Sitagliptin Phosphate | 200 | 41 |
| Losartan Potassium | Losartan Potassium | 189 | 58 |
| Atenolol | Atenolol | 181 | 49 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 180 | 178 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 27 |
| Donepezil Hcl | Donepezil Hcl | 168 | 19 |
| Xarelto | Rivaroxaban | 168 | 28 |
| Prednisone | Prednisone | 164 | 132 |
| Ozempic | Semaglutide | 161 | 31 |
| Warfarin Sodium | Warfarin Sodium | 159 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 157 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 59 |
| Simvastatin | Simvastatin | 147 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 134 | 37 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 130 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 129 | 26 |
| Mounjaro | Tirzepatide | 122 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 118 | 37 |
| Tradjenta | Linagliptin | 118 | 26 |
| Klor-Con M20 | Potassium Chloride | 115 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 27 |
| Irbesartan | Irbesartan | 109 | 27 |
| Chlorthalidone | Chlorthalidone | 103 | 29 |
| Myrbetriq | Mirabegron | 103 | 21 |
| Trazodone Hcl | Trazodone Hcl | 103 | 19 |
| Celecoxib | Celecoxib | 93 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 52 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 87 | 40 |
| Terazosin Hcl | Terazosin Hcl | 85 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 23 |
| Telmisartan | Telmisartan | 80 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 78 | 15 |
| Tramadol Hcl | Tramadol Hcl | 78 | 29 |
| Ramipril | Ramipril | 76 | 18 |
| Cefdinir | Cefdinir | 75 | 61 |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 59 |
| Glipizide Er | Glipizide | 66 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 32 |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 57 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 54 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 19 |
| Clonidine Hcl | Clonidine Hcl | 51 | suppressed |
| Mirtazapine | Mirtazapine | 51 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 50 | 50 |
| Unithroid | Levothyroxine Sodium | 50 | 17 |
| Meclizine Hcl | Meclizine Hcl | 46 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 25 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 43 | 43 |
| Glipizide | Glipizide | 43 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | 12 |
| Cephalexin | Cephalexin | 41 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Azithromycin | Azithromycin | 40 | 38 |
| Bumetanide | Bumetanide | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 11 |
| Spironolactone | Spironolactone | 37 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 34 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 16 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 20 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 27 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | 11 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Edarbi | Azilsartan Medoxomil | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Colchicine | Colchicine | 21 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Klor-Con M10 | Potassium Chloride | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | 17 |
| Kerendia | Finerenone | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Metronidazole | Metronidazole | 18 | 18 |
| Mirabegron Er | Mirabegron | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Mesalamine | Mesalamine | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 14 |
| Onglyza | Saxagliptin Hcl | 15 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 15 | 15 |
| Veltassa | Patiromer Calcium Sorbitex | 15 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | 11 |
| Calcitriol | Calcitriol | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,543.56 · 124 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, CAMZYOS, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, EDARBI, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, HORIZANT, INCEPTIV, INSPIRE, JARDIANCE, Kerendia, LOKELMA, M-M-R II, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, ULTOMIRIS, UNITHROID, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND, ZORYVE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error